For example, translational studies have demonstrated the efficacy of EphA2 kinase inhibitors [9,10] and EphA2-targeted cellular therapies [11,12,13] in preclinical models of NSCLC. This evidence concerns the gene EPHA2 and non-small cell lung carcinoma.